Kura Sushi USA KRUS 深 沪
等待开盘 12-27 09:30:00 美东时间
56.435
+0.975
+1.76%
华盛通- 最 高56.50
- 今 开55.44
- 成交量 13.92万股
- 最 低 54.61
- 昨 收 55.46
- 总市值 6.83亿
- 52周最高 106.60
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 40.03
- 委 比 98.02%
- 总股本 1209.39万
- 历史最高 122.81
- 量 比 0.57
- 振 幅 3.41%
- 历史最低 5.07
- 每 手 1
- 风险率 13.85%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Kura Sushi USA to Announce Fiscal First Quarter 2026 Financial Results on January 7, 2026
Kura Sushi USA will discuss its fiscal first quarter 2026 financial results during a conference call on Wednesday, January 7, 2026, at 5:00 p.m. ET. A press release with the financial results will be issued that day after market close. The call will be hosted by Hajime "Jimmy" Uba, Jeff Uttz, and Benjamin Porten. Participants can join via telephone at 201-689-8471 or via webcast at www.kurasushi.com under the Investor Relations section. A replay ...
12-17 14:00
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 17:17
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 10:22
Kura Sushi USA shares are trading higher after reporting better-than-expected Q4 financial results and raising FY 2025 sales guidance.
Kura Sushi USA shares are trading higher after reporting better-than-expected Q...
11-07 06:19
Earnings Scheduled For November 6, 2025
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
11-06 19:12
A Peek at Kura Sushi USA's Future Earnings
Kura Sushi USA (NASDAQ:KRUS) is gearing up to announce its quarterly earnings o...
11-06 03:01
美股大行评级 | 买入！Fermi、Neptune获多家大行首予评级；伯克希尔哈撒韦罕见地获得“卖出”评级；摩根大通上调苹果目标价升至290美元
今日重点评级关注：Guggenheim：上调Neumora Therapeutics评级至"买入"，目标价14美元；韦德布什：上调Fate Therapeutics评级至"跑赢大市"，目标价从5美元升至7美元
10-28 10:08
美股大行评级 | 超配！万事达、Visa、Block获多家机构首予评级；奈飞、德州仪器遭多家机构下调目标价
今日重点评级关注：Canaccord Genuity：维持ATAI Life Sciences"买入"评级，目标价从11美元升至14美元；麦格理：维持Cleanspark"跑赢大市"评级，目标价从20美元升至30美元
10-23 10:06
Barclays Maintains Equal-Weight on Kura Sushi USA, Lowers Price Target to $67
Barclays analyst Jeffrey Bernstein maintains Kura Sushi USA (NASDAQ:KRUS) with a Equal-Weight and lowers the price target from $75 to $67.
10-23 00:31
Keros Therapeutics Announces Plan for Return of $375 Million in Excess Capital
Keros Therapeutics has repurchased all shares held by ADAR1 Capital Management and Pontifax Venture Capital for approximately $181 million at $17.75 per share, with transactions closing on October 15, 2025. The company also plans to distribute 25% of net cash proceeds from its Takeda license agreement to shareholders and intends to commence a tender offer to repurchase up to $194 million of additional shares at the same price, subject to market c...
10-15 10:30
